Stock Analiz

Harmony Biosciences Holdings, Inc. (HRMY) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Harmony Biosciences’s revenue went from $6M in fiscal 2019 to $868M in fiscal 2025, growth of about 129.2% a year.

Net income in fiscal 2025 was $159M, a net margin of 18.3%; the best year in this period was 2022 with $181M.

Over the twelve months to September 30, 2026, revenue was $989M and net income $179M.

Free cash flow was $348M in fiscal 2025 and positive in 5 of the 7 years shown.

The diluted share count rose 653% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $6M20192020: $160M20202021: $305M20212022: $438M20222023: $582M20232024: $715M20242025: $868M2025$868M
Net income
2019: -$152M20192020: -$37M20202021: $35M20212022: $181M20222023: $129M20232024: $145M20242025: $159M2025$159M
Free cash flow
2019: -$76M20192020: -$3M20202021: $98M20212022: $144M20222023: $219M20232024: $219M20242025: $348M2025$348M
EPS (diluted)
2019: $-24.0720192020: $-2.4820202021: $0.5820212022: $2.9720222023: $2.1320232024: $2.5120242025: $2.712025$2.71

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$989M$868M$715M$582M$438M$305M$160M$6M
Gross profit$732M$670M$558M$461M$354M$250M$132M$4M
Operating income$219M$208M$191M$192M$120M$88M$17M-$146M
Net income$179M$159M$145M$129M$181M$35M-$37M-$152M
EPS (diluted)$3.03$2.71$2.51$2.13$2.97$0.58$-2.48$-24.07
R&D$238M$190M$146M$76M$71M$30M$19M$70M
Revenue growth—+21.5%+22.8%+32.9%+43.4%+91.2%+2564.6%—

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow$323M$348M$220M$219M$144M$99M-$3M-$75M
Capital spending-$648000-$310000-$1M-$312000-$172000-$298000-$2000-$149000
Free cash flow$323M$348M$219M$219M$144M$98M-$3M-$76M
Dividends paid—$0$0$0$0$0$0$0
Buybacks———$100M——$167000—
Stock-based pay$38M$45M$43M$32M$26M$16M$5M$10M

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$775M$467M$353M$323M$234M$229M$24M
Debt—$169M$181M$196M$194M$203M$194M$98M
Equity—$870M$659M$467M$403M$187M$97M-$423M
Total assets—$1.3B$999M$811M$674M$433M$427M$107M
Shares (diluted)60M59M58M60M61M59M26M8M

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin74.0%77.2%78.1%79.2%80.9%81.8%82.6%73.7%
Operating margin22.2%24.0%26.7%33.0%27.5%28.7%10.6%-2433.8%
Net margin18.1%18.3%20.4%22.1%41.4%11.3%-23.1%-2535.1%
FCF margin32.6%40.1%30.6%37.6%33.0%32.2%-1.9%-1260.8%
ROIC—14.8%17.2%21.5%15.9%20.8%4.6%—
ROE—18.2%22.1%27.6%45.1%18.6%-38.0%35.9%

Frequently asked questions

What is Harmony Biosciences’s annual revenue?

$868M in fiscal 2025 and $989M over the twelve months to September 30, 2026.

How much profit does Harmony Biosciences make?

Net income was $159M in fiscal 2025 (net margin 18.3%).

Is Harmony Biosciences’s revenue growing?

Yes: revenue rose 21.5% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.